Amphista Therapeutics

Amphista Therapeutics, a biopharmaceutical company based at BioCity in North Lanarkshire, creates first-in-class therapeutics, based on targeted protein degradation (TPD), that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins.

Backed by Advent Life Sciences, along with Forbion, Gilde Healthcare, Novartis Venture Fund, BioMotiv and Eli Lilly & Company, Amphista is a spin-out from the laboratory of Professor Alessio Ciulli, University of Dundee.  It develops drugs using ground-breaking TPD technology from Professor Ciulli’s research and has become a leading next-generation TPD company, rapidly working to advance a portfolio of innovative therapeutic candidates from early stage discovery to clinical stage research and commercialisation.

The company offers the potential to build on the progress of current TPD approaches and overcome many of their limitations, providing the opportunity to expand their therapeutic applications, reduce the risk of tumour resistance, and improve their druglike properties of the medicines. This allows them to to treat a wider range of diseases and concentrate on the translation of their novel TPD approach for clinical benefit in areas of high unmet need.

Amphista Therapeutics aims to increase its growing pipeline of potent and highly versatile bifunctional molecules, known as ‘Amphistas’, to the clinic and to extend its proprietary next-generation TPD platform. In practice this means that Amphista Therapeutics has the potential to produce innovative therapies that will efficiently remove disease-causing proteins from human cells and allow new treatments for a broad range of diseases with high efficacy and reduced potential for drug resistance.